ml0c00010_si_001.pdf (2.42 MB)
Strategic Incorporation of Polarity in Heme-Displacing Inhibitors of Indoleamine-2,3-dioxygenase‑1 (IDO1)
journal contribution
posted on 2020-03-13, 17:33 authored by Catherine White, Meredeth A. McGowan, Hua Zhou, Nunzio Sciammetta, Xavier Fradera, Jongwon Lim, Elizabeth M. Joshi, Christine Andrews, Elliott B. Nickbarg, Phillip Cowley, Sarah Trewick, Martin Augustin, Konstanze von Köenig, Charles A. Lesburg, Karin Otte, Ian Knemeyer, Hyun Woo, Wensheng Yu, Mangeng Cheng, Peter Spacciapoli, Prasanthi Geda, Xuelei Song, Nadya Smotrov, Patrick Curran, Mee Ra Heo, Pravien Abeywickrema, J. Richard Miller, David Jonathan Bennett, Yongxin HanIndoleamine-2,3-dioxygenase-1
(IDO1) has emerged as a target of
significant interest to the field of cancer immunotherapy, as the
upregulation of IDO1 in certain cancers has been linked to host immune
evasion and poor prognosis for patients. In particular, IDO1 inhibition
is of interest as a combination therapy with immune checkpoint inhibition.
Through an Automated Ligand Identification System (ALIS) screen, a
diamide class of compounds was identified as a promising lead for
the inhibition of IDO1. While hit 1 possessed attractive
cell-based potency, it suffered from a significant right-shift in
a whole blood assay, poor solubility, and poor pharmacokinetic properties.
Through a physicochemical property-based approach, including a focus
on lowering AlogP98 via the strategic introduction of polar
substitution, compound 13 was identified bearing a pyridyl
oxetane core. Compound 13 demonstrated improved whole
blood potency and solubility, and an improved pharmacokinetic profile
resulting in a low predicted human dose.
History
Usage metrics
Categories
Keywords
cell-based potencyCompound 13blood potencypharmacokinetic profileIDO 1.Automated Ligand Identification SystemIDO 1 inhibitionblood assayAlogP 98compound 13pharmacokinetic propertiesStrategic Incorporationcombination therapysolubilitydiamide classcancer immunotherapypyridyl oxetane coreIndoleamineHeme-Displacing InhibitorsIDO 1physicochemical property-based approachcheckpoint inhibitionALIS
Licence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC